Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01666808 | FACBC Outcomes for Post Prostatectomy | completed | Phase 2 / Phase 3 | 165 | Emory UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03658447 |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) |
| completed |
| Phase 1 / Phase 2 |
| 37 |
| Peter MacCallum Cancer Centre, AustraliaOTHER |
| 1 |
| Jul 28, 2023 |
| clinicaltrials |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00003871 | PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 60 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005847 | Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003614 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT00866554 | Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy | completed | Phase 2 | 60 | CHU de Quebec-Universite LavalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT00987753 | Study Evaluating the Safety and Tolerability of L-377202 | completed | Phase 1 / Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT00583752 | Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21(APP21) | completed | Phase 2 | 50 | David M LubaroffOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT02058706 | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | completed | Phase 2 | 71 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT01278914 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03429244 | PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer | completed | Phase 2 | 36 | Indiana UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT00114985 | Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT01751438 | Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) | completed | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 27, 2023 | clinicaltrials |
| NCT02159950 | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02624518 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 122 | Andrei IagaruOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05806853 | PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study | completed | Phase 2 | 60 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02278055 | Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03679260 | Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance | completed | Phase 2 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03103152 | A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression(PROVENT) | completed | Phase 2 / Phase 3 | 104 | Queen Mary University of LondonOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04179968 | The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer | completed | Phase 2 | 20 | Dana MathewsOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01385059 | Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer | completed | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03043807 | A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04627896 | Targeted Microwave Focal Therapy | completed | Phase 2 / Phase 3 | 11 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01903408 | Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment(PLATIN) | completed | Phase 2 | 199 | Heidelberg UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02311049 | Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01921803 | Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer(Hypofraction) | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT00547339 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 94 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02680587 | Stereotactic Body Radiation for Prostate Oligometastases(ORIOLE) | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT02598895 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | completed | Phase 2 | 14 | University of WashingtonOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02649439 | Prostvac in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02176161 | Metformin Prostate Cancer Adjuvant Trial | completed | Phase 2 | 59 | NYU Langone HealthOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01717053 | Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer | completed | Phase 2 | 37 | Duke UniversityOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT02789878 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | completed | Phase 2 | 64 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | completed | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02716974 | A Study of Definitive Therapy to Treat Prostate Cancer(oligo-mets) | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04424654 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy(PSMA-BAT) | completed | Phase 2 | 20 | Hospital Sirio-LibanesOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 2, 2023source: clinicaltrials